• Pfizer’s investigational oral JAK-3 inhibitor, CP-690,550, works in rheumatoid arthritis. [Bloomberg]

• GSK starts vaccine-focused JV with Chinese company Shenzhen Neptunus Interlong Bio-Technique Co. [MarketWatch]

• GSK’s over-the-counter weight loss drug Alli might go the way of the DoDo. [PharmaMarketingBlog]

• Eli Lilly racist? NAACP files lawsuit. [Pharmalive]

• Hey! Biotech didn’t get a bailout, just SBIRs… [The Deal]

• Kamada reports positive proof of concept data from phase 2, proof of concept study with its Inhaled Alpha-1 Antitrypsin (AAT) in bronchiectasis. [BusinessWire]

• MDRNA shares double after FDA approves generic calcitonin-salmon nasal spray. [Reuters]

• Daiichi needs acquisitions to survive! [Bloomberg]

• Finally, an ex-Bristol-Myers Squibb exec has been sentenced to write a book detailing how he came to lie to the Feds about Plavix. [WSJ Health Blog]

Anonymous Tip? Comments? Contact us: hr AT iguanabio DOT com

Related Posts